Ann Hanna1, Justin M Balko2. 1. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 2. Department of Medicine, Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, TN, USA. justin.balko@vumc.org.
Abstract
PURPOSE: The clinical implementation of immunotherapy has profoundly transformed cancer treatment. Targeting the immune system to mount anti-tumor responses can elicit a systemically durable response. Employing immune checkpoint blockade (ICB) has suppressed tumor growth and vastly improved patient overall and progression-free survival in several cancer types, most notably melanoma and non-small cell lung carcinoma. Despite widescale clinical success, ICB response is heterogeneously efficacious across tumor types. Many cancers, including breast cancer, are frequently refractory to ICB. In this review, we will discuss the challenges facing immunotherapy success and address the underlying mechanisms responsible for primary and acquired breast cancer resistance to immunotherapy. FINDINGS: Even in initially ICB-responsive tumors, many acquire resistance due to tumor-specific alterations, loss of tumor-specific antigens, and extrinsic mechanisms that reshape the immune landscape within the tumor microenvironment (TME). The tumor immune interaction circumvents the benefits of immunotherapy; tumors rewire the tumor-suppressive functions of activated immune cells within their stroma to propagate tumor growth and progression. CONCLUSIONS: The breast cancer immune TME is complex and the mechanisms driving resistance to ICB are multifaceted. Continued study in both preclinical models and clinical trials should help elucidate these mechanisms so they can be targeted to benefit more breast cancer patients.
PURPOSE: The clinical implementation of immunotherapy has profoundly transformed cancer treatment. Targeting the immune system to mount anti-tumor responses can elicit a systemically durable response. Employing immune checkpoint blockade (ICB) has suppressed tumor growth and vastly improved patient overall and progression-free survival in several cancer types, most notably melanoma and non-small cell lung carcinoma. Despite widescale clinical success, ICB response is heterogeneously efficacious across tumor types. Many cancers, including breast cancer, are frequently refractory to ICB. In this review, we will discuss the challenges facing immunotherapy success and address the underlying mechanisms responsible for primary and acquired breast cancer resistance to immunotherapy. FINDINGS: Even in initially ICB-responsive tumors, many acquire resistance due to tumor-specific alterations, loss of tumor-specific antigens, and extrinsic mechanisms that reshape the immune landscape within the tumor microenvironment (TME). The tumor immune interaction circumvents the benefits of immunotherapy; tumors rewire the tumor-suppressive functions of activated immune cells within their stroma to propagate tumor growth and progression. CONCLUSIONS: The breast cancer immune TME is complex and the mechanisms driving resistance to ICB are multifaceted. Continued study in both preclinical models and clinical trials should help elucidate these mechanisms so they can be targeted to benefit more breast cancerpatients.
Authors: Maryam Althobiti; Mohammed A Aleskandarany; Chitra Joseph; Michael Toss; Nigel Mongan; Maria Diez-Rodriguez; Christopher C Nolan; Ibraheem Ashankyty; Ian O Ellis; Andrew R Green; Emad A Rakha Journal: Histopathology Date: 2018-10-09 Impact factor: 5.087
Authors: Alberto Calabrò; Tim Beissbarth; Ruprecht Kuner; Michael Stojanov; Axel Benner; Martin Asslaber; Ferdinand Ploner; Kurt Zatloukal; Hellmut Samonigg; Annemarie Poustka; Holger Sültmann Journal: Breast Cancer Res Treat Date: 2008-07-01 Impact factor: 4.872
Authors: Matthew M Gubin; Xiuli Zhang; Heiko Schuster; Etienne Caron; Jeffrey P Ward; Takuro Noguchi; Yulia Ivanova; Jasreet Hundal; Cora D Arthur; Willem-Jan Krebber; Gwenn E Mulder; Mireille Toebes; Matthew D Vesely; Samuel S K Lam; Alan J Korman; James P Allison; Gordon J Freeman; Arlene H Sharpe; Erika L Pearce; Ton N Schumacher; Ruedi Aebersold; Hans-Georg Rammensee; Cornelis J M Melief; Elaine R Mardis; William E Gillanders; Maxim N Artyomov; Robert D Schreiber Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: Ruth Dannenfelser; Marianne Nome; Andliena Tahiri; Josie Ursini-Siegel; Hans Kristian Moen Vollan; Vilde D Haakensen; Åslaug Helland; Bjørn Naume; Carlos Caldas; Anne-Lise Børresen-Dale; Vessela N Kristensen; Olga G Troyanskaya Journal: Oncotarget Date: 2017-07-07
Authors: Tânia Ferreira-Gonçalves; Maria Manuela Gaspar; João M P Coelho; Vanda Marques; Ana S Viana; Lia Ascensão; Lina Carvalho; Cecília M P Rodrigues; Hugo Alexandre Ferreira; David Ferreira; Catarina Pinto Reis Journal: Biomolecules Date: 2022-01-04